Kraig Biocraft Laboratories Inc (Public, PINK:KBLB)

Sigma-Aldrich and Kraig Biocraft Laboratories Successfully Negotiate License Agreement

Sigma-Aldrich and Kraig to work together to create the next generation biomaterials.

Sigma-Aldrich Becomes Kraig Shareholder

LANSING , MI --4/12/2011 – Kraig Biocraft Laboratories, Inc. (Pinksheets: KBLB) announced today that the Company has entered into a licensing agreement with biotechnology giant Sigma-Aldrich (NASDAQ: SIAL), Inc.

Kraig has successfully negotiated a license to use Sigma-Aldrich's powerful zinc finger technology to accelerate its scientific research and product development, along with an option to commercialize the resulting biomaterials in the textile and biomedical fields.

“Sigma-Aldrich's proprietary zinc finger technologies are extremely powerful tools which enable very precise genetic targeting,” said Kraig's CEO Kim Thompson. “We are convinced that this technology is the key to creating advanced new products and materials. We believe that when these customized tools are delivered by Sigma in the coming weeks, the technology will enable us to rapidly and precisely target specific gene sequences for the creation of stronger fibers, advanced textiles and new bio-materials.”

“ZFN technology has been revolutionary in genome engineering for various applications, including animal models of disease, engineering of biopharmaceutical production systems, academic research and therapeutics,” said Dr. Joseph Bedell, Director of Sigma's Commercial Animal Technology Group. “Spider silk production is just the first example of a commercial animal application for this exciting technology.”

“Kraig has the utmost confidence in the power of Sigma's zinc finger technology,” said Mr. Thompson. “Sigma's agreeing to provide this technology by virtue of the licensing agreement to Kraig, is a real boost for us, and for the future of bio-materials and spider silk technology. We negotiated this agreement not only to accelerate our development of advanced materials, but also because I believe that Sigma's zinc finger technology will reinforce Kraig's competitive advantage in the field of bio-materials and advanced silk polymers. Kraig Biocraft Laboratories expectation is that the combination of Sigma-Aldrich's revolutionary technology and know-how, coupled with Kraig's proprietary bio-materials technology and know-how, will create synergies that will benefit both companies.

Sigma ® Life Science and Kraig Biocraft Laboratories to Develop Silkworms for the Production of Spider Silk

Sigma's CompoZr ® ZFN technology expected to enable targeted insertion of spider silk genes and the removal of endogenous silkworm genes

St. Louis, MO. – April 12, 2011 – Sigma Life Science, the innovative biological products and services research business of Sigma-Aldrich ® (Nasdaq:SIAL), today announced the signing of an agreement with Kraig Biocraft Laboratories, Inc. (KBLB) to develop genetically modified silkworms for the production of spider silk, using Sigma's proprietary CompoZr Zinc Finger Nuclease (ZFN) technology. The transfer of silk genes from the spider to the silkworm is expected to allow the mass production of silk with enhanced strength and elasticity with potential textiles and biomedical applications, such as sutures, tendon and ligament repair, bulletproof vests, and automobile airbags.

Since the first published sequence of a spider silk gene in 1990, much research has focused on the production of commercially viable spider silk with high tensile strength and elasticity. In 2010 KBLB made an important advance towards this goal, by producing hybrid silkworms with randomly inserted spider silk genes, yielding hybrid spider­silkworm silk with greater strength and durability than native silkworm silk. The precise gene targeting and high efficiency of Sigma's ZFN technology allow s KBLB to build on its revolutionary proof of concept research, by concomitantly targeting the insertion of spider silk genes into the silkworm genome while removing endogenous silkworm silk genes. The resulting transgenic silkworm is expected to be capable of spinning pure spider silk at commercially viable production levels.

“ZFN technology has been revolutionary in genome engineering for various applications, including animal models of disease, engineering of biopharmaceutical production systems, academic research and therapeutics,” said Dr. Joseph Bedell, Director of Sigma Life Science's Commercial Animal Technologies Group. “Spider silk production is just the first example of a potential commercial animal application for this exciting technology, perfectly positioning Sigma Life Science as a leading provider of innovative technologies that are changing the face of science and improving the quality of life.”

Company Report:

http://www.kraiglabs.com/pdf/Emerging%20Growth%20Stock%20Report%20on%20K...

Rating: Strong Buy

Price Targets:

Short Term: $0.40

Long Term Price target

Depending on Lab

Developments: $2.50+

One of the major hurdles that most biotechnology companies must overcome is the FDA approval

process. Because Kraig Biocraft Laboratories does not need FDA approval, we believe it will be much

easier for investors to monetize their investment should a major breakthrough be achieved in the

laboratory.

Shares of Kraig Biocraft Laboratories are clearly speculative, but offer some exciting appreciation

possibilities in the future. It will surely be exciting to watch developments at this company over the

coming weeks, months and years.

Kraig Biocraft Laboratories Announces That Raymond Kutsunai Has Joined Its Business Advisory Board

Renowned Former SmithKline & French Laboratories Executive Joins Kraig Advisory Board

LANSING, MI, Nov 22, 2010 (MARKETWIRE via COMTEX) -- Kraig Biocraft Laboratories, Inc. (pinksheets:KBLB) announced today that Raymond Kutsunai, the former general manager of SmithKline & French Laboratories, Japan, has joined the Company's Board of Advisors.

Mr. Kutsunai was a central figure in SmithKline & French Laboratories operations and spectacular growth in Japan. Kutsunai is the second former major executive from SmithKline to join Kraig Biocraft Laboratories' advisory board. Earlier this month SmithKline Beecham's celebrated former CEO and Chairman Henry Wendt joined the Company's Board of Advisors. SmithKline Beecham, which became Glaxo SmithKline, is one of the world's largest and most successful corporations.

"Kraig Biocraft Laboratories is privileged to be able to attract this extraordinary level of talent," said the Company's founder and CEO Kim K. Thompson. "We are particularly excited about bringing Mr. Kutsunai onto the team. He rightfully deserves his stellar reputation in Japan for accomplishment and integrity. In addition to his extensive business experience and leadership Mr. Kutsunai also has extensive contacts in Japan which may prove to be invaluable as our Company grows. His proven record for orchestrating and managing explosive growth is exactly what we need as we move to commercialize our technologies."

--------------------------------

Kraig Biocraft Laboratories Announces That Henry Wendt Has Joined Its Business Advisory Board

Renowned Fortune 500 CEO Joins Kraig Advisory Board

LANSING, MI, Nov 09, 2010 (MARKETWIRE via COMTEX) -- Kraig Biocraft Laboratories, Inc. (pinksheets:KBLB) announced today that Henry Wendt, the renowned former head of SmithKline Beecham, has joined the Company's Board of Advisors.

Wendt is the former CEO and Chairman of SmithKline Beecham, one of the world's largest and most successful corporations. He has an unparalleled track record for fostering and managing corporate growth through mergers and acquisitions, as well as through organic growth and global marketing. In fact, he is generally recognized as the principal architect of the successful merger which created SmithKline Beecham.

"Henry Wendt is one of the top CEOs on the planet, with a proven Fortune 500 track record," said Kraig Biocraft Laboratories CEO, Kim K. Thompson. "In addition to his groundbreaking leadership at SmithKline Beecham, he literally wrote the book on successful strategies for corporate growth in the global marketplace. Mr. Wendt's book Global Embrace: Corporate Challenges in a Transnational World is, in my opinion, a 'must read' for corporate executives. We are very fortunate and excited to have him on our team. I know that, as a member of our advisory board, his insight and advice will be invaluable, as we grow and commercialize our revolutionary technologies."

gewinnt langsam wieder an fahrt.. netter schlussspurt

rückkehr richtung MA 20 vorstellbar, kaufgelegenheit bei 0.105 herum!?

MA 50 und 200 verlaufen gerade nahezu aufeinander..

Kraig Biocraft Laboratories to Hold Shareholder Conference Call to Discuss Laboratory, Technical and Commercialization Updates

Kraig Biocraft Labs (QB) (USOTC:KBLB)

Today : Wednesday 25 May 2011

Kraig Biocraft Laboratories, Inc. (PINKSHEETS: KBLB) announces today that Kim Thompson cordially invites all interested parties to participate in the Company's conference call to be held on Friday, June 10, 2011 at 4:30 p.m. EDT.

Thompson, the Company's CEO and Founder, will review the recent Sigma-Aldrich agreement and upcoming laboratory developments, as well as what is in the recombinant spider silk commercialization pipeline, followed by a question and answer period.

The conference call phone number and other details, including access codes, will be announced in a follow-up company release on the morning of the call. Shareholders are invited to submit questions to benh@ttfsco.com and must be received by Thursday, June 9, to be considered.

About Kraig Biocraft Laboratories

Kraig Biocraft Laboratories is a fully reporting biotechnology company that recently achieved a series of scientific breakthroughs, with implications for the global textile industry. For further information please visit www.KraigLabs.com.

Kraig Biocraft Laboratories Announces the Successful Creation of New Commercial Hybrid Transgenic Silkworms

Date : 05/31/2011 @ 6:05AM

Source : MarketWire

Stock : Kraig Biocraft Laboratories, Inc. (KBLB)

Quote : 0.133 0.0 (0.00%) @ 8:38AM

Kraig Biocraft Laboratories Announces the Successful Creation of New Commercial Hybrid Transgenic Silkworms

Kraig Biocraft Labs (QB) (USOTC:KBLB)

Intraday Stock Chart

Today : Tuesday 31 May 2011

Click Here for more Kraig Biocraft Labs (QB) Charts.

Kraig Biocraft Laboratories, Inc. (PINKSHEETS: KBLB) announced that it successfully mated its transgenic silkworms, which produce recombinant spider silk, with a physically larger commercial strain of the domesticated silkworm. The resulting hybrid silkworms are larger than Kraig's original transgenic silkworms and are also producing significantly larger recombinant silk cocoons.

Independent laboratory testing confirmed that the transgenic/commercial silkworm hybrids are producing silk which is significantly stronger and more flexible than that of the original commercial strain. The new recombinant spider silk is a composite silk composed of both native silkworm silk proteins and spider silk proteins (as in the original Kraig transgenic silkworm whose development was announced in late September).

Kim Thompson, the Company's CEO and Founder, stated, "The new hybrid was specifically designed for commercialization and has been designated 'Monster Hybrid,' which is the successful cross between our transgenic silkworms and a much larger commercial strain.

"The result is a large, robust, commercial sized silkworm which spins a larger commercial sized cocoon composed of recombinant spider silk like the original transgenic. The new hybrid was specifically designed to generate greater recombinant silk production capacity than our original first generation transgenic."

"This larger hybrid transgenic will be the platform for our commercialization ramp up," Thompson continued. "Now that the strength and elasticity qualities have been confirmed, we can move forward with cultivating the hybrids in commercially viable quantities. We are working diligently to increase our stock of the new strain in order to increase our production capacity."

gell, sag ich schon lange

WARSICS wrote:

bin wieder mit dabei. .137 in

na dann gl. bin gespannt auf CC

hoffe der schreit nicht nach geld. Wär schön wenn Sigma-Aldrich mal was hinblättern würde..

nice kleiner break out

grad gelesen..

Kraig Biocraft Laboratories (KBLB) – We are expecting great news from KBLB. The Company is hosting a conference call next week on Friday June 10th at 4:30 pm EST where we expect them to talk about the specifics of the commercial rollout of the hybrid silk product. Among the many topics surrounding this new development, we also expect Kraig Biocraft to start shedding light on some of the details on who the Company will be partnering with in the industry for the ultimate launch into market, including the garment sector among others. When we originally issued our research report, back when the shares were only a few cents, we placed a price target of $0.40 on the shares. We now think that price target is probably too conservative. At $0.40, the total market capitalization of Kraig Biocraft is approximately $220 million. We believe this market capitalization is supportable relative to revolutionizing silk production for the garment industry alone. China exports between $3 billion and $5 billion of silk fabric into the garment industry each year. Having a technology that could easily affect only 20% of this market would impact approximately $800 million of revenues each year. We think KBLB will develop as we have outlined previously – garment industry first and high tech products second. Should be a very good conference call.

http://www.joenoelstocks.com/stocks-covered/options-media-group-holdings...

WARSICS wrote:

würde die untere trendlinie EXAKT so ziehen. danke für die arbeit boon. hast du noch nachgeladen oder einfach noch aus den guten alten zeiten liegen lassen?

moin

die letzten bei 0.105 genommen. hab knapp 100k stk.

hehe auch schon wach oder immer noch?

Dr. David Kaplan Joins Kraig Biocraft Laboratories Scientific Advisory Board

Date : 06/06/2011 @ 6:05AM

Source : MarketWire

Stock : Kraig Biocraft Laboratories, Inc. (KBLB)

Quote : 0.173 0.013 (8.12%) @ 11:59AM

Dr. David Kaplan Joins Kraig Biocraft Laboratories Scientific Advisory Board

Kraig Biocraft Labs

Kraig Biocraft Laboratories, Inc. (PINKSHEETS: KBLB) announced today that celebrated biomedical researcher Dr. David Kaplan, whose research interest focuses on the interface between biology and materials science, with over 35 years of scientific applications research experience, has joined the Company's Board of Scientific Advisors.

Dr. Kaplan is internationally recognized for his work relating to biomedical and other applications for spider silk and biopolymers. He is the Chairman of Tufts University's Department of Biomedical Engineering and is the Director of the Bioengineering and Biotechnology Center. His research focus is on biopolymer engineering to understand structure-function relationships, with emphasis on studies related to self-assembly, biomaterials engineering and functional tissue engineering. He has published more than 400 papers and edited eight books.

Renowned for his outstanding accomplishments and contributions in the realms of science and biomedical engineering, Dr. Kaplan has been awarded numerous honors and awards including Elected Fellow, American Institute of Medical and Biological Engineering; Outstanding Faculty Award, Tufts University and the Decoration for Meritorious Civilian Service, U.S. Government.

"We are very happy to announce that Dr. Kaplan has agreed to join our board of Scientific Advisors," said Kraig Biocraft Laboratories founder and CEO, Kim K. Thompson. "There is an obvious synergy between the Kraig's work in developing and producing recombinant spider silk and Dr. Kaplan's work in researching and developing practical applications for biopolymers including spider silk."

Thompson continued, "We have always been fortunate in being able to attract the top intellects and talent to both our Scientific Board of Advisors and our Business Board of Advisors. Dr. Kaplan's proven track record in the science of biopolymers and biopolymer applications makes him ideally suited to advise us as we move toward the production of our own spider silk based biopolymers."

Additionally, the Company reminds all interested parties that it will host an informational teleconference on Friday, June 10, 2011 at 4:30 p.m. EDT. Interested parties are invited to submit questions to benh@ttfsco.com by Thursday, June 9. Call in details, including phone number and access codes, will be announced in a follow-up company release on the morning of the call

welcome doc Kaplan

nich schlecht.. anfang april noch für 0.06/7 zu haben, nun schon wieder auf knapp 0.2..

ich schätze dass kommt erst noch ganz dicK

0.19 mausert sich grad zum widerstand

WARSICS wrote:

jau! 2. angriff!

das könnt was werden

baah war das n langer tag..

aber es sieht gut aus..